Overview Financials News + Filings Key Docs Charts Ownership Insiders
|
|
AMAG PHARMACEUTICALS, INC. (AMAG)
|
Add to portfolio |
|
|
|
| Price: |
$13.71
| | Metrics |
| OS: |
34.7
|
M
| |
-16
|
% ROE
|
| Market cap: |
$476
|
M
| |
10
|
% ROIC
|
|
Net debt:
|
$120
|
M
| |
3.2
|
x Debt/EBITDA
|
|
EV:
|
$597
|
M
| | | |
| | | | | |
| TTM Valuation | | | |
|
EBITDA
|
$37.1
|
M
| |
16.1
|
x EV/EBITDA
|
|
EBIT
|
$5.4
|
M
| |
111.5
|
x EV/EBIT
|
| EPS |
($1.21)
| |
|
|
|
|
| |
|
|
|
Recent News + Filings (All items)
|
Revenue Mix by Segment
|
Financial Summary (All financials)
| In millions, except per share items | Dec-31-19 | Dec-31-18 | Dec-31-17 | Dec-31-16 | Dec-31-15 | Dec-31-14 | Dec-31-13 | Dec-31-12 |
| Revenues | 326.5 | 472.0 | 494.0 | 432.5 | 418.3 | 124.4 | 80.9 | 85.4 |
| Revenue growth | -30.8% | -4.4% | 14.2% | 3.4% | 236.3% | 53.8% | -5.3% | 39.4% |
| Cost of goods sold | 107.2 | 230.0 | 161.3 | 96.3 | 88.5 | 20.3 | 12.0 | 14.2 |
| Gross profit | 219.4 | 242.0 | 332.6 | 336.2 | 329.8 | 104.1 | 68.9 | 71.2 |
| Gross margin | 67.2% | 51.3% | 67.3% | 77.7% | 78.8% | 83.7% | 85.2% | 83.3% |
| Selling, general and administrative | 286.6 | 227.8 | 178.2 | 169.5 | 160.3 | 72.3 | 59.2 | 53.1 |
| Research and development | 64.9 | 44.8 | 75.0 | 65.6 | 42.9 | 24.2 | 20.6 | 33.3 |
| EBITA | -107.3 | 229.0 | 209.9 | 173.4 | 180.1 | 12.8 | -10.8 | -15.2 |
| EBITA margin | -32.9% | 48.5% | 42.5% | 40.1% | 43.1% | 10.3% | -13.4% | -17.8% |
| Amortization of intangibles | 24.8 | 158.4 | 130.4 | 72.3 | 53.5 | 5.1 | | |
| EBIT | -132.1 | 70.6 | 79.5 | 101.1 | 126.6 | 7.7 | -10.8 | -15.2 |
| EBIT margin | -40.5% | 15.0% | 16.1% | 23.4% | 30.3% | 6.2% | -13.4% | -17.8% |
| Pre-tax income | -467.7 | -131.6 | -382.2 | 15.3 | 39.8 | -17.3 | -9.6 | -17.6 |
| Income taxes | 0.0 | 40.4 | -175.5 | 13.2 | 7.1 | -153.2 | 0.0 | 0.0 |
| Tax rate | 0.0% | | 45.9% | 86.3% | 17.7% | 883.2% | 0.0% | 0.0% |
| Net income | -467.7 | -68.5 | -200.8 | -2.5 | 32.8 | 135.8 | -9.6 | -16.8 |
| Net margin | -143.2% | -14.5% | -40.6% | -0.6% | 7.8% | 109.2% | -11.9% | -19.6% |
| |
| Diluted EPS | ($13.74) | ($5.00) | ($5.92) | $0.06 | $0.93 | $5.38 | ($0.44) | ($0.78) |
| Shares outstanding (diluted) | 34.0 | 34.4 | 34.9 | 34.8 | 35.3 | 25.2 | 21.7 | 21.4 |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |
|
|